Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma

Cancer Cell

Volumn 26, Issue 1, 2014, Pages 33-47

  Vanner, RobertJ ^a,b,c   Remke, Marc ^a,b,c   Gallo, Marco ^a,b   Selvadurai, HaydenJ ^a,b   Coutinho, Fiona ^a,b,c   Lee, Lilian ^a,b   Kushida, Michelle ^a,b   Head, Renee ^a,b   Morrissy, Sorana ^a,b   Zhu, Xueming ^a,b   Aviv, Tzvi ^a,b   Voisin, Veronique ^c   Clarke, IanD ^a,b,d   Li, Yisu ^e   Mungall, AndrewJ ^e   Moore, RichardA ^e   Ma, Yussanne ^e   Jones, StevenJ M ^e   Marra, MarcoA ^e   Malkin, David ^f   Northcott, PaulA ^g   Kool, Marcel ^g   Pfister, StefanM ^g,h   Bader, Gary ^c   Hochedlinger, Konrad ^i,j   Korshunov, Andrey ^g,k   Taylor, MichaelD ^a,b,c   Dirks, PeterB ^a,b,c   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HSC   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d OCAD UNIVERSITY   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^j HARVARD STEM CELL INSTITUTE   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITHRAMYCIN; NEURON SPECIFIC NUCLEAR PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL; TUMOR GROWTH;

ERINACEIDAE;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; CELL LINEAGE; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; NEUROGENESIS; NEUROPEPTIDES; NUCLEAR PROTEINS; PLICAMYCIN; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SOXB1 TRANSCRIPTION FACTORS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84904264545     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.005     Document Type: Article

References (56)

1. Ahlfeld J., Favaro R., Pagella P., Kretzschmar H.A., Nicolis S., Schüller U. Sox2 requirement in sonic hedgehog-associated medulloblastoma. Cancer Res. 2013, 73:3796-3807.
2. Arnold K., Sarkar A., Yram M.A., Polo J.M., Bronson R., Sengupta S., Seandel M., Geijsen N., Hochedlinger K. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell 2011, 9:317-329.
3. Bailey P., Cushing H. Medulloblastoma cerebelli: A common type of midcerebellar glioma of childhood. Arch. Neurol. Psychiatry 1925, 14:192-224.
4. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
5. Crawford J.R., MacDonald T.J., Packer R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007, 6:1073-1085.
6. Doetsch F., García-Verdugo J.M., Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J.Neurosci. 1997, 17:5046-5061.
7. Doetsch F., Caillé I., Lim D.A., García-Verdugo J.M., Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999, 97:703-716.
8. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
9. Ellis P., Fagan B.M., Magness S.T., Hutton S., Taranova O., Hayashi S., McMahon A., Rao M., Pevny L. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev. Neurosci. 2004, 26:148-165.
10. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
11. Garcia I., Crowther A.J., Gama V., Ryan Miller C., Deshmukh M., Gershon T.R. Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation. Oncogene 2013, 32:2304-2314.
12. Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., Woll P., Mead A., Alford K.A., Rout R., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
13. Goff D.J., Court Recart A., Sadarangani A., Chun H.J., Barrett C.L., Krajewska M., Leu H., Low-Marchelli J., Ma W., Shih A.Y., et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013, 12:316-328.
14. Goodrich L.V., Milenković L., Higgins K.M., Scott M.P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113.
15. Grotzer M.A., Janss A.J., Fung K., Biegel J.A., Sutton L.N., Rorke L.B., Zhao H., Cnaan A., Phillips P.C., Lee V.M., Trojanowski J.Q. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J.Clin. Oncol. 2000, 18:1027-1035.
16. Guan Y., Gerhard B., Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149.
17. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma invivo. Genes Dev. 2008, 22:436-448.
18. Hatten M.E., Roussel M.F. Development and cancer of the cerebellum. Trends Neurosci. 2011, 34:134-142.
19. Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
20. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J.Immunol. Methods 2009, 347:70-78.
21. Ito K., Bernardi R., Morotti A., Matsuoka S., Saglio G., Ikeda Y., Rosenblatt J., Avigan D.E., Teruya-Feldstein J., Pandolfi P.P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
22. Kool M., Jones D.T., Jäger N., Northcott P.A., Pugh T.J., Hovestadt V., Piro R.M., Esparza L.A., Markant S.L., Remke M., et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014, 25:393-405. ICGC PedBrain Tumor Project.
23. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
24. Laks D.R., Masterman-Smith M., Visnyei K., Angenieux B., Orozco N.M., Foran I., Yong W.H., Vinters H.V., Liau L.M., Lazareff J.A., et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009, 27:980-987.
25. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
26. Li P., Du F., Yuelling L.W., Lin T., Muradimova R.E., Tricarico R., Wang J., Enikolopov G., Bellacosa A., Wechsler-Reya R.J., Yang Z.J. A population of Nestin-expressing progenitors in the cerebellum exhibits increased tumorigenicity. Nat. Neurosci. 2013, 16:1737-1744.
27. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K., Clarke M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N.Engl. J. Med. 2007, 356:217-226.
28. LoRusso P.M., Rudin C.M., Reddy J.C., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Chang I., Darbonne W.C., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 2011, 17:2502-2511.
29. Martynoga B., Mateo J.L., Zhou B., Andersen J., Achimastou A., Urbán N., van den Berg D., Georgopoulou D., Hadjur S., Wittbrodt J., et al. Epigenomic enhancer annotation reveals a key role for NFIX in neural stem cell quiescence. Genes Dev. 2013, 27:1769-1786.
30. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
31. Merlos-Suárez A., Barriga F.M., Jung P., Iglesias M., Céspedes M.V., Rossell D., Sevillano M., Hernando-Momblona X., da Silva-Diz V., Muñoz P., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
32. Ming G.L., Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011, 70:687-702.
33. Miyahara H., Natsumeda M., Yoshimura J., Ogura R., Okazaki K., Toyoshima Y., Fujii Y., Takahashi H., Kakita A. Neuronal differentiation associated with Gli3 expression predicts favorable outcome for patients with medulloblastoma. Neuropathology 2014, 34:1-10.
34. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
35. Northcott P.A., Jones D.T., Kool M., Robinson G.W., Gilbertson R.J., Cho Y.J., Pomeroy S.L., Korshunov A., Lichter P., Taylor M.D., Pfister S.M. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 2012, 12:818-834.
36. O'Brien C.A., Kreso A., Ryan P., Hermans K.G., Gibson L., Wang Y., Tsatsanis A., Gallinger S., Dick J.E. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 2012, 21:777-792.
37. Panosyan E.H., Laks D.R., Masterman-Smith M., Mottahedeh J., Yong W.H., Cloughesy T.F., Lazareff J.A., Mischel P.S., Moore T.B., Kornblum H.I. Clinical outcome in pediatric glial and embryonal brain tumors correlates with invitro multi-passageable neurosphere formation. Pediatr. Blood Cancer 2010, 55:644-651.
38. Partap S., Murphy P.A., Vogel H., Barnes P.D., Edwards M.S., Fisher P.G. Liposomal cytarabine for central nervous system embryonal tumors in children and young adults. J.Neurooncol. 2011, 103:561-566.
39. Pazzaglia S., Tanori M., Mancuso M., Rebessi S., Leonardi S., Di Majo V., Covelli V., Atkinson M.J., Hahn H., Saran A. Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice. Oncogene 2006, 25:1165-1173.
40. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., Morrison S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
41. Read T.A., Fogarty M.P., Markant S.L., McLendon R.E., Wei Z., Ellison D.W., Febbo P.G., Wechsler-Reya R.J. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
42. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
43. Robarge K.D., Brunton S.A., Castanedo G.M., Cui Y., Dina M.S., Goldsmith R., Gould S.E., Guichert O., Gunzner J.L., Halladay J., et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 2009, 19:5576-5581.
44. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
45. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N.Engl. J. Med. 2009, 361:1173-1178.
46. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., Najima Y., Takagi S., Aoki Y., Wake A., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
47. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
48. Schüller U., Heine V.M., Mao J., Kho A.T., Dillon A.K., Han Y.G., Huillard E., Sun T., Ligon A.H., Qian Y., et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14:123-134.
49. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
50. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
51. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
52. Suvà M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi A.S., Cahill D.P., Nahed B.V., et al. Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell 2014, 157:580-594.
53. Ward R.J., Lee L., Graham K., Satkunendran T., Yoshikawa K., Ling E., Harper L., Austin R., Nieuwenhuis E., Clarke I.D., et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009, 69:4682-4690.
54. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
55. Zeltzer P.M., Boyett J.M., Finlay J.L., Albright A.L., Rorke L.B., Milstein J.M., Allen J.C., Stevens K.R., Stanley P., Li H., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J.Clin. Oncol. 1999, 17:832-845.
56. Zheng Y., de la Cruz C.C., Sayles L.C., Alleyne-Chin C., Vaka D., Knaak T.D., Bigos M., Xu Y., Hoang C.D., Shrager J.B., et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013, 24:59-74.